Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience will collaborate on a two-year, 2,000-patient liquid biopsy lung cancer screening project in Japan, using cfDNA and cfRNA testing.
Tel Aviv University researchers have developed a low-cost blood test that detects lung cancer by analyzing optical DNA fingerprints, achieving 93.1% sensitivity and 90.3% specificity.
Cancer Cell Diagnostics has launched the CellSight DNA test, a liquid biopsy that isolates intact circulating tumor cells for genomic profiling from a single blood draw, enabling analysis of over 500 genes and key biomarkers.
A Johns Hopkins study finds that a single liquid biopsy within nine weeks of immunotherapy start can predict long-term survival in advanced lung cancer, providing results months earlier than standard imaging.
Read More
A Cedars-Sinai study in JAMA Network Open reports women testing negative for BRCA mutations but with a family cancer history face a 25% lifetime breast cancer risk, underscoring the importance of family history in risk assessment.
Read More
A peer-reviewed study validates Astrin Biosciences’ Certitude test, which uses proteomics and machine learning to detect early-stage breast cancer with 92.6% sensitivity and 92.3% specificity.
Read More
10x Genomics and Lausanne University Hospital have begun a multi-year study using single cell and spatial technologies to identify biomarkers predicting treatment response in patients with advanced solid tumors.
Read More
YD Bio and Numia Health have launched a six-month pilot in British Columbia to evaluate cross-border blood-based cancer testing, supporting up to 50 patient episodes with laboratory analysis performed at a CLIA-certified U.S. facility.
Read More
Nabsys and Indiana University School of Medicine have launched a multi-year collaboration to develop electronic genome mapping applications for acute myeloid leukemia and myelodysplastic syndromes.
Read More
RNA-based testing improves detection of MET exon 14 skipping in NSCLC, identifying mutations missed by DNA-only assays, according to new research. Findings may impact eligibility for targeted therapies.
Read More
Labcorp has announced the upcoming launch of the Marker by Labcorp Genetic Health Panel, which will analyze 163 genes linked to over 100 medically actionable conditions, with results supported by licensed genetic counselors.
Read More
The company is showcasing newly cleared tests and platforms for multiple myeloma, lung cancer, connective tissue disease, and other laboratory applications.
Read More
Researchers report that inherited CDK12 gene variants may increase risk for early, aggressive prostate cancer, suggesting inclusion of CDK12 in hereditary screening panels could improve risk identification in men.
Read More
Ibex Medical Analytics has received IVDR certification for its breast cancer diagnostic tools, completing regulatory approval for ER, PR, and Ki67 tests, according to a company press release.
Read More
The test uses intact circulating tumor cells instead of cell-free DNA fragments to analyze more than 500 genes and identify tumor markers.
Read More
The assay is designed to detect minimal residual disease with greater sensitivity than conventional flow cytometry.
Read More
A new study in The Journal of Nuclear Medicine reports that a noninvasive DNA blood test can help select advanced prostate cancer patients most likely to benefit from 223Ra radiopharmaceutical therapy and monitor treatment response.
Read More
The deal adds a blood-based test for viral-mediated cancers to the company’s portfolio of transplant and cell therapy services.
Read More